{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T23:20:11Z","timestamp":1768346411103,"version":"3.49.0"},"reference-count":43,"publisher":"Walter de Gruyter GmbH","issue":"3","license":[{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,10,25]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec id=\"j_pp-2019-0007_s_001a_w2aab3b7b1b1b6b1aab1c16b1Aa\">\n                    <jats:title id=\"d1310192e422_w2aab3b7b1b1b6b1aab1c16b1aAa\">Background<\/jats:title>\n                    <jats:p>Early postoperative intraperitoneal chemotherapy (EPIC) can be used in combination with cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) to treat patients with peritoneal carcinomatosis (PC) of multiple origins. The present study is a systematic review to evaluate the role of EPIC after CRS\u2009+\u2009HIPEC for appendiceal and colorectal cancers with PC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_pp-2019-0007_s_002a_w2aab3b7b1b1b6b1aab1c16b2Aa\">\n                    <jats:title id=\"d1310192e431_w2aab3b7b1b1b6b1aab1c16b2aAa\">Content<\/jats:title>\n                    <jats:p>We conducted a systematic search in PubMed according to the PRISMA guidelines and included all studies published before June 27 of 2019 comparing EPIC to HIPEC or the combination of both. Our search found 79 articles. After excluding non-relevant articles, a total of 13 retrospective clinical studies reporting on the efficacy and safety of EPIC compared to HIPEC or as a combination therapy for lower gastrointestinal neoplasms were analyzed. Initial EPIC reports led to its declined usage because of concerns with increased postoperative morbidity and uncertain added benefit on survival. Recent retrospective studies have been promising, showing significant improvements in OS and fewer issues with complications when adding EPIC to CRS\u2009+\u2009HIPEC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_pp-2019-0007_s_003a_w2aab3b7b1b1b6b1aab1c16b3Aa\">\n                    <jats:title id=\"d1310192e440_w2aab3b7b1b1b6b1aab1c16b3aAa\">Conclusions<\/jats:title>\n                    <jats:p>Current evidence is entirely retrospective and is conflicting. It is hoped that ongoing clinical trials and additional studies will clarify EPIC\u2019s role in the treatment of patients with PC.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1515\/pp-2019-0007","type":"journal-article","created":{"date-parts":[[2019,10,4]],"date-time":"2019-10-04T05:02:42Z","timestamp":1570165362000},"source":"Crossref","is-referenced-by-count":22,"title":["Early postoperative intraperitoneal chemotherapy for lower gastrointestinal neoplasms with peritoneal metastasis: a systematic review and critical analysis"],"prefix":"10.1515","volume":"4","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4576-5774","authenticated-orcid":false,"given":"Mikael L.","family":"Soucisse","sequence":"first","affiliation":[{"name":"Department of Surgery , University of New South Wales, St George Hospital , Kogarah , New South Wales , Australia"},{"name":"Department of Surgery , H\u00f4pital Maisonneuve-Rosemont, Universit\u00e9 de Montr\u00e9al , Montreal , Quebec , Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Winston","family":"Liauw","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology , University of New South Wales, St George Hospital , Kogarah , New South Wales , Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabrielle","family":"Hicks","sequence":"additional","affiliation":[{"name":"Department of Surgery , University of New South Wales, St George Hospital , Kogarah , New South Wales , Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David L.","family":"Morris","sequence":"additional","affiliation":[{"name":"Department of Surgery , University of New South Wales, St George Hospital , Kogarah , New South Wales , Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"374","published-online":{"date-parts":[[2019,10,4]]},"reference":[{"key":"2025120909273568523_j_pp-2019-0007_ref_001_w2aab3b7b1b1b6b1ab1b7b1Aa","doi-asserted-by":"crossref","unstructured":"Verwaal VJ, Bruin S, Boot H, van Slooten G, van Tinteren H. 8-year follow-up of randomized trial: cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy in patients with peritoneal carcinomatosis of colorectal cancer. Ann Surg Oncol 2008;15:2426\u201332.1852168610.1245\/s10434-008-9966-2","DOI":"10.1245\/s10434-008-9966-2"},{"key":"2025120909273568523_j_pp-2019-0007_ref_002_w2aab3b7b1b1b6b1ab1b7b2Aa","doi-asserted-by":"crossref","unstructured":"Stephens FO, Storey DW, Thompson JF, Marsden FW. Surgical oncology and the role of regional chemotherapy. Aust N Z J Surg 1992;62:691\u20136.10.1111\/j.1445-2197.1992.tb07064.x1520150","DOI":"10.1111\/j.1445-2197.1992.tb07064.x"},{"key":"2025120909273568523_j_pp-2019-0007_ref_003_w2aab3b7b1b1b6b1ab1b7b3Aa","doi-asserted-by":"crossref","unstructured":"Van der Speeten K, Stuart OA, Sugarbaker PH. Pharmacokinetics and pharmacodynamics of perioperative cancer chemotherapy in peritoneal surface malignancy. Cancer J 2009;15:216\u201324.1955690810.1097\/PPO.0b013e3181a58d95","DOI":"10.1097\/PPO.0b013e3181a58d95"},{"key":"2025120909273568523_j_pp-2019-0007_ref_004_w2aab3b7b1b1b6b1ab1b7b4Aa","doi-asserted-by":"crossref","unstructured":"Ortega-Deballon P, Facy O, Jambet S, Magnin G, Cotte E, Beltramo JL, et al. Which method to deliver hyperthermic intraperitoneal chemotherapy with oxaliplatin? An experimental comparison of open and closed techniques. Ann Surg Oncol 2010;17:1957\u201363.10.1245\/s10434-010-0937-z20143265","DOI":"10.1245\/s10434-010-0937-z"},{"key":"2025120909273568523_j_pp-2019-0007_ref_005_w2aab3b7b1b1b6b1ab1b7b5Aa","doi-asserted-by":"crossref","unstructured":"Avital I, Brucher BL, Nissan A, Stojadinovic A. Randomized clinical trials for colorectal cancer peritoneal surface malignancy. Surg Oncol Clin N Am 2012;21:665\u201388.2302172310.1016\/j.soc.2012.07.004","DOI":"10.1016\/j.soc.2012.07.004"},{"key":"2025120909273568523_j_pp-2019-0007_ref_006_w2aab3b7b1b1b6b1ab1b7b6Aa","doi-asserted-by":"crossref","unstructured":"Goere D, Malka D, Tzanis D, Gava V, Boige V, Eveno C, et al. Is there a possibility of a cure in patients with colorectal peritoneal carcinomatosis amenable to complete cytoreductive surgery and intraperitoneal chemotherapy? Ann Surg 2013;257:1065\u201371.10.1097\/SLA.0b013e31827e9289","DOI":"10.1097\/SLA.0b013e31827e9289"},{"key":"2025120909273568523_j_pp-2019-0007_ref_007_w2aab3b7b1b1b6b1ab1b7b7Aa","doi-asserted-by":"crossref","unstructured":"Overgaard J. Effect of hyperthermia on malignant cells in vivo. Rev Hypothesis Cancer 1977;39:2637\u201346.","DOI":"10.1002\/1097-0142(197706)39:6<2637::AID-CNCR2820390650>3.0.CO;2-S"},{"key":"2025120909273568523_j_pp-2019-0007_ref_008_w2aab3b7b1b1b6b1ab1b7b8Aa","doi-asserted-by":"crossref","unstructured":"Buell JF, Reed E, Lee KB, Parker RJ, Venzon DJ, Amikura K, et al. Synergistic effect and possible mechanisms of tumor necrosis factor and cisplatin cytotoxicity under moderate hyperthermia against gastric cancer cells. Ann Surg Oncol 1997;4:141\u20138.10.1007\/BF023037979084851","DOI":"10.1007\/BF02303797"},{"key":"2025120909273568523_j_pp-2019-0007_ref_009_w2aab3b7b1b1b6b1ab1b7b9Aa","doi-asserted-by":"crossref","unstructured":"Glehen O, Kwiatkowski F, Sugarbaker PH, Elias D, Levine EA, De Simone M, et al. Cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for the management of peritoneal carcinomatosis from colorectal cancer: a multi-institutional study. J Clin Oncol 2004;22:3284\u201392.1531077110.1200\/JCO.2004.10.012","DOI":"10.1200\/JCO.2004.10.012"},{"key":"2025120909273568523_j_pp-2019-0007_ref_010_w2aab3b7b1b1b6b1ab1b7c10Aa","doi-asserted-by":"crossref","unstructured":"McConnell YJ, Mack LA, Francis WP, Ho T, Temple WJ. HIPEC\u2009+\u2009EPIC versus HIPEC-alone: differences in major complications following cytoreduction surgery for peritoneal malignancy. J Surg Oncol 2013;107:591\u20136.2312953310.1002\/jso.23276","DOI":"10.1002\/jso.23276"},{"key":"2025120909273568523_j_pp-2019-0007_ref_011_w2aab3b7b1b1b6b1ab1b7c11Aa","doi-asserted-by":"crossref","unstructured":"Quenet F, Goere D, Mehta SS, Roca L, Dumont F, Hessissen M, et al. Results of two bi-institutional prospective studies using intraperitoneal oxaliplatin with or without irinotecan during HIPEC after cytoreductive surgery for colorectal carcinomatosis. Ann Surg 2011;254:294\u2013301.2177212910.1097\/SLA.0b013e3182263933","DOI":"10.1097\/SLA.0b013e3182263933"},{"key":"2025120909273568523_j_pp-2019-0007_ref_012_w2aab3b7b1b1b6b1ab1b7c12Aa","doi-asserted-by":"crossref","unstructured":"Tan GH, Ong WS, Chia CS, Tham CK, Soo KC, Teo MC. Does early post-operative intraperitoneal chemotherapy (EPIC) for patients treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) make a difference? Int J Hyperthermia 2016;32:281\u20138.2686266710.3109\/02656736.2015.1135485","DOI":"10.3109\/02656736.2015.1135485"},{"key":"2025120909273568523_j_pp-2019-0007_ref_013_w2aab3b7b1b1b6b1ab1b7c13Aa","doi-asserted-by":"crossref","unstructured":"Sparks DS, Morris B, Xu W, Fulton J, Atkinson V, Meade B, et al. Cytoreductive surgery and heated intraperitoneal chemotherapy for peritoneal carcinomatosis secondary to mucinous adenocarcinoma of the appendix. Int Surg 2015;100:21\u20138.10.9738\/INTSURG-D-14-00089.125594636","DOI":"10.9738\/INTSURG-D-14-00089.1"},{"key":"2025120909273568523_j_pp-2019-0007_ref_014_w2aab3b7b1b1b6b1ab1b7c14Aa","doi-asserted-by":"crossref","unstructured":"Elias D, Benizri E, Di Pietrantonio D, Menegon P, Malka D, Raynard B. Comparison of two kinds of intraperitoneal chemotherapy following complete cytoreductive surgery of colorectal peritoneal carcinomatosis. Ann Surg Oncol 2007;14:509\u201314.10.1245\/s10434-006-9167-917096054","DOI":"10.1245\/s10434-006-9167-9"},{"key":"2025120909273568523_j_pp-2019-0007_ref_015_w2aab3b7b1b1b6b1ab1b7c15Aa","doi-asserted-by":"crossref","unstructured":"Lam JY, McConnell YJ, Rivard JD, Temple WJ, Mack LA. Hyperthermic intraperitoneal chemotherapy + early postoperative intraperitoneal chemotherapy versus hyperthermic intraperitoneal chemotherapy alone: assessment of survival outcomes for colorectal and high-grade appendiceal peritoneal carcinomatosis. Am J Surg 2015;210:424\u201330.10.1016\/j.amjsurg.2015.03.00826051744","DOI":"10.1016\/j.amjsurg.2015.03.008"},{"key":"2025120909273568523_j_pp-2019-0007_ref_016_w2aab3b7b1b1b6b1ab1b7c16Aa","doi-asserted-by":"crossref","unstructured":"Sorensen O, Flatmark K, Reed W, Wiig JN, Dueland S, Giercksky KE, et al. Evaluation of complete cytoreductive surgery and two intraperitoneal chemotherapy techniques in pseudomyxoma peritonei. Eur J Surg Oncol 2012;38:969\u201376.10.1016\/j.ejso.2012.06.55222763244","DOI":"10.1016\/j.ejso.2012.06.552"},{"key":"2025120909273568523_j_pp-2019-0007_ref_017_w2aab3b7b1b1b6b1ab1b7c17Aa","doi-asserted-by":"crossref","unstructured":"Cashin PH, Graf W, Nygren P, Mahteme H. Intraoperative hyperthermic versus postoperative normothermic intraperitoneal chemotherapy for colonic peritoneal carcinomatosis: a case-control study. Ann Oncol 2012;23:647\u201352.2168541310.1093\/annonc\/mdr301","DOI":"10.1093\/annonc\/mdr301"},{"key":"2025120909273568523_j_pp-2019-0007_ref_018_w2aab3b7b1b1b6b1ab1b7c18Aa","doi-asserted-by":"crossref","unstructured":"Sugarbaker PH, Chang D. Long-term regional chemotherapy for patients with epithelial malignant peritoneal mesothelioma results in improved survival. Eur J Surg Oncol 2017;43:1228\u201335.10.1016\/j.ejso.2017.01.00928189456","DOI":"10.1016\/j.ejso.2017.01.009"},{"key":"2025120909273568523_j_pp-2019-0007_ref_019_w2aab3b7b1b1b6b1ab1b7c19Aa","doi-asserted-by":"crossref","unstructured":"Huang Y, Alzahrani NA, Liauw W, Soudy H, Alzahrani AM, Morris DL. Early postoperative intraperitoneal chemotherapy is associated with survival benefit for appendiceal adenocarcinoma with peritoneal dissemination. Eur J Surg Oncol 2017;43:2292\u20138.10.1016\/j.ejso.2017.09.00229017824","DOI":"10.1016\/j.ejso.2017.09.002"},{"key":"2025120909273568523_j_pp-2019-0007_ref_020_w2aab3b7b1b1b6b1ab1b7c20Aa","doi-asserted-by":"crossref","unstructured":"Huang Y, Alzahrani NA, Liauw W, Traiki TB, Morris DL. Early postoperative intraperitoneal chemotherapy for low-grade appendiceal mucinous neoplasms with pseudomyxoma peritonei: is it beneficial? Ann Surg Oncol 2017;24:176\u201383.2771803210.1245\/s10434-016-5529-0","DOI":"10.1245\/s10434-016-5529-0"},{"key":"2025120909273568523_j_pp-2019-0007_ref_021_w2aab3b7b1b1b6b1ab1b7c21Aa","doi-asserted-by":"crossref","unstructured":"Chua TC, Liauw W, Zhao J, Morris DL. Comparative analysis of perioperative intraperitoneal chemotherapy regimen in appendiceal and colorectal peritoneal carcinomatosis. Int J Clin Oncol 2013;18:439\u201346.10.1007\/s10147-012-0397-522415741","DOI":"10.1007\/s10147-012-0397-5"},{"key":"2025120909273568523_j_pp-2019-0007_ref_022_w2aab3b7b1b1b6b1ab1b7c22Aa","doi-asserted-by":"crossref","unstructured":"Chua TC, Moran BJ, Sugarbaker PH, Levine EA, Glehen O, Gilly FN, et al. Early- and long-term outcome data of patients with pseudomyxoma peritonei from appendiceal origin treated by a strategy of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. J Clin Oncol 2012;30:2449\u201356.10.1200\/JCO.2011.39.716622614976","DOI":"10.1200\/jco.2012.30.4_suppl.532"},{"key":"2025120909273568523_j_pp-2019-0007_ref_023_w2aab3b7b1b1b6b1ab1b7c23Aa","doi-asserted-by":"crossref","unstructured":"Huang Y, Alzahrani NA, Fisher OM, Chua TC, Kozman MA, Liauw W, et al. Intraoperative macroscopic tumour consistency is associated with overall survival after cytoreductive surgery and intraperitoneal chemotherapy for appendiceal adenocarcinoma with peritoneal metastases: a retrospective observational study. Am J Surg 2019;217:704\u201312.10.1016\/j.amjsurg.2018.12.03730704669","DOI":"10.1016\/j.amjsurg.2018.12.037"},{"key":"2025120909273568523_j_pp-2019-0007_ref_024_w2aab3b7b1b1b6b1ab1b7c24Aa","unstructured":"Sideris L, Mitchell A, Drolet P, Leblanc G, Leclerc YE, Dube P. Surgical cytoreduction and intraperitoneal chemotherapy for peritoneal carcinomatosis arising from the appendix. Can J Surg 2009;52:135\u201341.19399209"},{"key":"2025120909273568523_j_pp-2019-0007_ref_025_w2aab3b7b1b1b6b1ab1b7c25Aa","doi-asserted-by":"crossref","unstructured":"Elias D, Gilly F, Boutitie F, Quenet F, Bereder JM, Mansvelt B, et al. Peritoneal colorectal carcinomatosis treated with surgery and perioperative intraperitoneal chemotherapy: retrospective analysis of 523 patients from a multicentric French study. J Clin Oncol 2010;28:63\u20138.1991786310.1200\/JCO.2009.23.9285","DOI":"10.1200\/JCO.2009.23.9285"},{"key":"2025120909273568523_j_pp-2019-0007_ref_026_w2aab3b7b1b1b6b1ab1b7c26Aa","doi-asserted-by":"crossref","unstructured":"Saxena A, Yan TD, Morris DL. A critical evaluation of risk factors for complications after cytoreductive surgery and perioperative intraperitoneal chemotherapy for colorectal peritoneal carcinomatosis. World J Surg 2010;34:70\u20138.1976031710.1007\/s00268-009-0206-0","DOI":"10.1007\/s00268-009-0206-0"},{"key":"2025120909273568523_j_pp-2019-0007_ref_027_w2aab3b7b1b1b6b1ab1b7c27Aa","unstructured":"Sugarbaker PH, Cunliffe WJ, Belliveau J, de Bruijn EA, Graves T, Mullins RE, et al. Rationale for integrating early postoperative intraperitoneal chemotherapy into the surgical treatment of gastrointestinal cancer. Semin Oncol 1989;16:83\u201397.2669141"},{"key":"2025120909273568523_j_pp-2019-0007_ref_028_w2aab3b7b1b1b6b1ab1b7c28Aa","doi-asserted-by":"crossref","unstructured":"Cunliffe WJ, Sugarbaker PH. Gastrointestinal malignancy: rationale for adjuvant therapy using early postoperative intraperitoneal chemotherapy. Br J Surg 1989;76:1082\u201390.10.1002\/bjs.18007610302688796","DOI":"10.1002\/bjs.1800761030"},{"key":"2025120909273568523_j_pp-2019-0007_ref_029_w2aab3b7b1b1b6b1ab1b7c29Aa","unstructured":"Sugarbaker PH, Graves T, DeBruijn EA, Cunliffe WJ, Mullins RE, Hull WE, et al. Early postoperative intraperitoneal chemotherapy as an adjuvant therapy to surgery for peritoneal carcinomatosis from gastrointestinal cancer: pharmacological studies. Cancer Res 1990;50:5790\u20134.2118420"},{"key":"2025120909273568523_j_pp-2019-0007_ref_030_w2aab3b7b1b1b6b1ab1b7c30Aa","doi-asserted-by":"crossref","unstructured":"Pestieau SR, Schnake KJ, Stuart OA, Sugarbaker PH. Impact of carrier solutions on pharmacokinetics of intraperitoneal chemotherapy. Cancer Chemother Pharmacol 2001;47:269\u201376.1132067210.1007\/s002800000214","DOI":"10.1007\/s002800000214"},{"key":"2025120909273568523_j_pp-2019-0007_ref_031_w2aab3b7b1b1b6b1ab1b7c31Aa","doi-asserted-by":"crossref","unstructured":"Van der Speeten K, Govaerts K, Stuart OA, Sugarbaker PH. Pharmacokinetics of the perioperative use of cancer chemotherapy in peritoneal surface malignancy patients. Gastroenterol Res Pract 2012;2012:378064.22778722","DOI":"10.1155\/2012\/378064"},{"key":"2025120909273568523_j_pp-2019-0007_ref_032_w2aab3b7b1b1b6b1ab1b7c32Aa","doi-asserted-by":"crossref","unstructured":"Loriot MA, Ciccolini J, Thomas F, Barin-Le-Guellec C, Royer B, Milano G, et al. [Dihydropyrimidine dehydrogenase (DPD) deficiency screening and securing of fluoropyrimidine-based chemotherapies: update and recommendations of the French GPCO-Unicancer and RNPGx networks]. Bull Cancer 2018;105:397\u2013407.29486921","DOI":"10.1016\/j.bulcan.2018.02.001"},{"key":"2025120909273568523_j_pp-2019-0007_ref_033_w2aab3b7b1b1b6b1ab1b7c33Aa","doi-asserted-by":"crossref","unstructured":"Klaver YL, Hendriks T, Lomme RM, Rutten HJ, Bleichrodt RP, de Hingh IH. Intraoperative versus early postoperative intraperitoneal chemotherapy after cytoreduction for colorectal peritoneal carcinomatosis: an experimental study. Ann Surg Oncol 2012;19:S475\u201382.2183752810.1245\/s10434-011-1984-9","DOI":"10.1245\/s10434-011-1984-9"},{"key":"2025120909273568523_j_pp-2019-0007_ref_034_w2aab3b7b1b1b6b1ab1b7c34Aa","doi-asserted-by":"crossref","unstructured":"Park SY, Choi GS, Park JS, Kim HJ, Yang CS, Kim JG, et al. Efficacy of early postoperative intraperitoneal chemotherapy after complete surgical resection of peritoneal metastasis from colorectal cancer: a case-control study from a single center. Ann Surg Oncol 2016;23:2266\u201373.2695114810.1245\/s10434-016-5148-9","DOI":"10.1245\/s10434-016-5148-9"},{"key":"2025120909273568523_j_pp-2019-0007_ref_035_w2aab3b7b1b1b6b1ab1b7c35Aa","doi-asserted-by":"crossref","unstructured":"Armstrong DK, Bundy B, Wenzel L, Huang HQ, Baergen R, Lele S, et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med 2006;354:34\u201343.10.1056\/NEJMoa05298516394300","DOI":"10.1056\/NEJMoa052985"},{"key":"2025120909273568523_j_pp-2019-0007_ref_036_w2aab3b7b1b1b6b1ab1b7c36Aa","doi-asserted-by":"crossref","unstructured":"Yu W, Whang I, Chung HY, Averbach A, Sugarbaker PH. Indications for early postoperative intraperitoneal chemotherapy of advanced gastric cancer: results of a prospective randomized trial. World J Surg 2001;25:985\u201390.1157198010.1007\/s00268-001-0067-7","DOI":"10.1007\/s00268-001-0067-7"},{"key":"2025120909273568523_j_pp-2019-0007_ref_037_w2aab3b7b1b1b6b1ab1b7c37Aa","doi-asserted-by":"crossref","unstructured":"Verwaal VJ, van Ruth S, de Bree E, van Sloothen GW, van Tinteren H, Boot H, et al. Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. J Clin Oncol 2003;21:3737\u201343.1455129310.1200\/JCO.2003.04.187","DOI":"10.1200\/JCO.2003.04.187"},{"key":"2025120909273568523_j_pp-2019-0007_ref_038_w2aab3b7b1b1b6b1ab1b7c38Aa","doi-asserted-by":"crossref","unstructured":"Levine EA, Votanopoulos KI, Shen P, Russell G, Fenstermaker J, Mansfield P, et al. A multicenter randomized trial to evaluate hematologic toxicities after hyperthermic intraperitoneal chemotherapy with oxaliplatin or mitomycin in patients with appendiceal tumors. J Am Coll Surg 2018;226:434\u201343.2933166310.1016\/j.jamcollsurg.2017.12.027","DOI":"10.1016\/j.jamcollsurg.2017.12.027"},{"key":"2025120909273568523_j_pp-2019-0007_ref_039_w2aab3b7b1b1b6b1ab1b7c39Aa","doi-asserted-by":"crossref","unstructured":"Hansen F, Berntsen GKR, Salamonsen A. \u201cWhat matters to you?\u201d A longitudinal qualitative study of Norwegian patients\u2019 perspectives on their pathways with colorectal cancer. Int J Qual Stud Health Well-being 2018;13:1548240.3070437510.1080\/17482631.2018.1548240","DOI":"10.1080\/17482631.2018.1548240"},{"key":"2025120909273568523_j_pp-2019-0007_ref_040_w2aab3b7b1b1b6b1ab1b7c40Aa","doi-asserted-by":"crossref","unstructured":"Ihemelandu C, Mavros MN, Sugarbaker P. Adverse events postoperatively had no impact on long-term survival of patients treated with cytoreductive surgery with heated intraperitoneal chemotherapy for appendiceal cancer with peritoneal metastases. Ann Surg Oncol 2016;23:4231\u20137.10.1245\/s10434-016-5355-427338748","DOI":"10.1245\/s10434-016-5355-4"},{"key":"2025120909273568523_j_pp-2019-0007_ref_041_w2aab3b7b1b1b6b1ab1b7c41Aa","doi-asserted-by":"crossref","unstructured":"Lee L, Alie-Cusson F, Dube P, Sideris L. Postoperative complications affect long-term outcomes after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal peritoneal carcinomatosis. J Surg Oncol 2017;116:236\u201343.2840983110.1002\/jso.24632","DOI":"10.1002\/jso.24632"},{"key":"2025120909273568523_j_pp-2019-0007_ref_042_w2aab3b7b1b1b6b1ab1b7c42Aa","doi-asserted-by":"crossref","unstructured":"Baratti D, Kusamura S, Iusco D, Bonomi S, Grassi A, Virzi S, et al. Postoperative complications after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy affect long-term outcome of patients with peritoneal metastases from colorectal cancer: a two-center study of 101 patients. Dis Colon Rectum 2014;57:858\u201368.10.1097\/DCR.000000000000014924901687","DOI":"10.1097\/DCR.0000000000000149"},{"key":"2025120909273568523_j_pp-2019-0007_ref_043_w2aab3b7b1b1b6b1ab1b7c43Aa","doi-asserted-by":"crossref","unstructured":"Amrhein V, Greenland S, McShane B. Scientists rise up against statistical significance. Nature 2019;567:305\u20137.3089474110.1038\/d41586-019-00857-9","DOI":"10.1038\/d41586-019-00857-9"}],"container-title":["Pleura and Peritoneum"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.degruyter.com\/view\/journals\/pp\/4\/3\/article-20190007.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/pp-2019-0007\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/pp-2019-0007\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T11:05:37Z","timestamp":1765278337000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/pp-2019-0007\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9,1]]},"references-count":43,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2019,10,11]]},"published-print":{"date-parts":[[2019,10,25]]}},"alternative-id":["10.1515\/pp-2019-0007"],"URL":"https:\/\/doi.org\/10.1515\/pp-2019-0007","relation":{},"ISSN":["2364-768X","2364-7671"],"issn-type":[{"value":"2364-768X","type":"electronic"},{"value":"2364-7671","type":"print"}],"subject":[],"published":{"date-parts":[[2019,9,1]]},"article-number":"20190007"}}